Skip to main content
Caplight Logo









Sofregen Medical

Sofregen Medical

Private
Framingham, MassachusettsHealthcare & Life Scienceshttps://www.sofregen.com/

Last Round

Series B

Dec 17, 2019

Total Funding Raised

$15.8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Sofregen Medical is a biotechnology company that develops a platform of products based on silk protein for soft tissue support and regeneration.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Advanced Materials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

soft tissue regenerationsilk protein platformbiomaterialsvocal fold augmentationinjectable implantsoft tissue bulking agentregenerative medicinetissue engineeringvoice carelaryngologymedical devicesvocal fold insufficiencybiocompatible implantsresorbable biomaterialinjectable filleraesthetic medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sofregen Medical Comparables

Compare Sofregen Medical with similar companies based on industry and business-model similarity.

Sofregen Medical comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Merz
81%
APrevent Medical Inc.
72%
Serigen Mediproducts
69%

Sofregen Medical Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 17, 2019
Series ASep 15, 2016
DebtSep 15, 2016
SeedSep 1, 2016

Sofregen Medical Investors

Notable investors and investment history

Sofregen Medical investors
InvestorRounds
Anzu PartnersSeries B
Polaris PartnersSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased from 0 to 5, representing 63% of headcount.

  • May 15, 2026

    Monthly visitors increased 47% MoM.

Sofregen Medical Filings

Explore SEC and related filing metadata, where available.

Sofregen Medical filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Sofregen Medical's valuation, stock price, and market status.

Is Sofregen Medical a public or private company?

Sofregen Medical is a private company.

What is the current stock price of Sofregen Medical?

Sofregen Medical is a private company with no public stock price. No recent secondary market data is available.

How much is Sofregen Medical worth (valuation)?

Valuation information for Sofregen Medical is not publicly available.

Can I buy Sofregen Medical stock?

Sofregen Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Sofregen Medical's last funding round?

Sofregen Medical's most recent funding round was Series B on December 17, 2019.

Who are the main investors in Sofregen Medical?

Key investors in Sofregen Medical include Anzu Partners, Polaris Partners.

Will Sofregen Medical IPO soon?

No public IPO plans have been announced for Sofregen Medical.

How can I track Sofregen Medical secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sofregen Medical's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersFramingham, Massachusetts
Employee Range8
Year Founded2014
Last FundingDec 17, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?